Berstein G, Zhang Y, Berger Z, Kieras E, et al. A phase I, randomized, double-blind study to assess the safety, tolerability, and efficacy of the topical RORC2 inverse agonist PF-06763809 in participants with mild-to-moderate plaque psoriasis. Clin Exp Dermatol 2020 Aug 7. doi: 10.1111/ced.14412.
PMID: 32767679